Login / Signup

Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.

Koji NagaokaMasataka ShiraiKiyomi TaniguchiAkihiro HosoiChangbo SunYukari KobayashiKazuhiro MaejimaMasashi FujitaHidewaki NakagawaSachiyo NomuraKazuhiko Kakimi
Published in: Journal for immunotherapy of cancer (2021)
Deep phenotyping of YTN16 tumors identified a sequence of events on the axis CCL20->IL-17-producing cells->IL-17-neutrophil-angiogenesis->suppression of neoantigen-specific CD8+ T cells which was responsible for the lack of tumor rejection. IL-17 blockade together with anti-PD-1 mAb therapy eradicated these YTN16 tumors. Thus, the deep immunological phenotyping can guide immunotherapy for the tailored treatment of each individual patient's tumor.
Keyphrases